6.90Open6.90Pre Close0 Volume21 Open Interest22.50Strike Price0.00Turnover458.01%IV11.91%PremiumJan 17, 2025Expiry Date4.79Intrinsic Value100Multiplier9DDays to Expiry2.11Extrinsic Value100Contract SizeAmericanOptions Type-0.4791Delta0.0302Gamma2.08Leverage Ratio-0.2780Theta-0.0041Rho-1.00Eff Leverage0.0115Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet